This is a contrast between Zai Lab Limited (NASDAQ:ZLAB) and Ophthotech Corporation (:) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zai Lab Limited 34 0.00 30.82M -2.60 0.00
Ophthotech Corporation N/A 0.00 N/A 1.70 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Zai Lab Limited and Ophthotech Corporation.

Profitability

Table 2 represents Zai Lab Limited (NASDAQ:ZLAB) and Ophthotech Corporation (:)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zai Lab Limited 91,972,545.51% 0% 0%
Ophthotech Corporation 0.00% 0% 0%

Institutional & Insider Ownership

The shares of both Zai Lab Limited and Ophthotech Corporation are owned by institutional investors at 60.9% and 65.14% respectively. Zai Lab Limited’s share owned by insiders are 35.26%. Competitively, insiders own roughly 0.61% of Ophthotech Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zai Lab Limited -8.41% -11.66% 23.3% 19.14% 50.8% 38.33%
Ophthotech Corporation 0% 0% 0% 0% 0% 0%

Summary

On 5 of the 6 factors Zai Lab Limited beats Ophthotech Corporation.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *